Other lipid agents × cardiovascular events

SynthesisThe Cochrane database of systematic reviews2018

Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.

Shipeng Zhan et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 23,499 people · 2018

Randomised comparison

Reduced cardiovascular events

−6%−10% to −2%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.94, 95% CI 0.90–0.98

Randomised comparison

Reduced cardiovascular events

−12%−19% to −5%

Bigger than 2 in 10 for cardiovascular events

As reported

RR 0.88, 95% CI 0.81–0.95

Randomised comparison

Reduced cardiovascular events

−17%−29% to −3%

Bigger than 4 in 10 for cardiovascular events

As reported

RR 0.83, 95% CI 0.71–0.97

Randomised comparison

Reduced cardiovascular events

−6%−11% to −1%

Bigger than 1 in 10 for cardiovascular events

As reported

RR 0.94, 95% CI 0.89–0.99

+3 more in the walkthrough ↓

Seven numbers in the abstract

the abstract, start to end

with statins alone (risk ratio (RR) 0.94, 95% confidence interval (CI)

little or no effect on this outcome (RR 0.98, 95% CI 0.91 to 1.05; 21,222

non-fatal myocardial infarction (MI) (RR 0.88, 95% CI 0.81 to 0.95; a decrease from 105/1000 to 92/1000, 95% CI 85 to 100; 21,145 participants; 6 studies; moderate-quality evidence) and non-fatal stroke (RR 0.83, 95% CI 0.71 to 0.97; a

little or no effect on this outcome (RR 1.00, 95% CI 0.89 to 1.12; 19457

by adding ezetimibe to statin (RR 0.94, 95% CI 0.89 to 0.99; a decrease from 196/1000 to 184/1000, 95% 175 to 194; 21,323 participants; 7 studies); however, no difference in coronary revascularisation rate was observed when a sensitivity analysis was limited to studies with a low risk of bias.In terms of safety, adding ezetimibe to statins may make little or no difference in the risk of hepatopathy (RR 1.14, 95% CI 0.96 to 1.35; 20,687

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
RR 0.940.90–0.98
All-cause mortality
RR 0.980.91–1.05
Cardiovascular events
RR 0.880.81–0.95
Cardiovascular events
RR 0.830.71–0.97
Cardiovascular events
RR 1.000.89–1.12
Cardiovascular events
RR 0.940.89–0.99
Cardiovascular events
RR 1.140.96–1.35
StatinsOther lipid agentsCardiovascular eventsAll-cause mortality

Other lipid agents × cardiovascular eventshelps?settled

unlikelylikely
0.80not counted

Statins × cardiovascular eventshelps?replicated

unlikelylikely
0.86not counted

Other lipid agents × all-cause mortalityhelps?one trial

unlikelylikely
0.50not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

48 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 30480766